keyword
MENU ▼
Read by QxMD icon Read
search

Etanercept

keyword
https://www.readbyqxmd.com/read/28822784/a-novel-model-for-the-pharmacokinetic-studies-of-bevacizumab-and-etanercept-in-healthy-volunteers-and-patients
#1
Meizhen Li, Wei Qiang, Li Hu, Lei Wang, Zeneng Cheng
Therapeutic monoclonal antibodies (mAbs) have been successfully applied to treat various diseases and shown a promising prospect in medical treatment. MAbs have some unique characteristics comparing with small chemical drugs, and their pharmacokinetic (PK) properties are much more complex than those of small chemical drugs, whose eliminations are usually linear. In this study, a new model was established through taking into account the mechanisms of the elimination of mAbs. The proposed model was applied to the modeling and simulation of two kinds of mAbs, including bevacizumab and etanercept, in PK studies of healthy volunteers and eligible patients, and the classical linear compartment model was set as control...
August 16, 2017: Biochemical Pharmacology
https://www.readbyqxmd.com/read/28822031/advances-in-the-management-of-thyroid-eye-diseases-an-overview
#2
REVIEW
Rashmi Kumari, Bhawesh Chandra Saha
INTRODUCTION: Thyroid eye disease (TED) remains a notorious ailment for both patients and the treating ophthalmologists. Recent years have witnessed considerable research in the immunopathogenic mechanism of TED that has resulted in an expansion and modification of the available management options. AIM: Purpose of this review is to summarise the advances in the management of thyroid ophthalmopathy. MATERIAL AND METHOD: A thorough literature search and of the past 10 years web search with words Thyroid ophthalmopathy, recent, advances...
August 18, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28819122/anti-inflammatory-drugs-suppress-ultrasound-mediated-mesenchymal-stromal-cell-tropism-to-kidneys
#3
Scott R Burks, Ben A Nguyen, Michele N Bresler, Matthew E Nagle, Saejeong J Kim, Joseph A Frank
Mesenchymal stromal cells (MSC) are potential renal therapeutics. Clinically, results are mixed partly because MSC tropism to kidneys is minimal following infusion. Ultrasound augmentation of the renal microenvironment is becoming increasingly-important in renal MSC therapies. We demonstrated pulsed-focused-ultrasound (pFUS) increases enhanced homing permeability and retention of MSC in mouse kidneys. Here, we characterized the temporal proteomic response to pFUS in mouse kidneys and its association with MSC tropism...
August 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28814890/clinical-and-economic-analysis-of-outcomes-of-dose-tapering-or-withdrawal-of-tumor-necrosis-factor-%C3%AE-inhibitors-upon-achieving-stable-disease-activity-in-rheumatoid-arthritis-patients
#4
Daniel Aletaha, Sonya J Snedecor, Varun Ektare, Mei Xue, Yanjun Bao, Vishvas Garg
OBJECTIVE: To compare the real-world, 5-year clinical and cost impact of maintaining treatment with the tumor necrosis factor-α inhibitors (anti-TNFs) adalimumab, etanercept, or infliximab vs dose tapering or withdrawal in rheumatoid arthritis (RA) patients who have achieved remission (defined as a 28-joint count Disease Activity Score [DAS28] < 2.6) or low disease activity (LDA; DAS28 < 3.2). METHODS: Using a 5-year Markov model with 1-month cycle length, we examined the clinical and cost impact of three treatment strategies: withdrawal, tapering, or maintenance of anti-TNFs among RA patients in remission or who have achieved LDA...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28811745/inhibition-of-inflammation-mediated-through-the-tumor-necrosis-factor-%C3%AE-biochemical-pathway-can-lead-to-favorable-outcomes-in-alzheimer-disease
#5
REVIEW
Daniah Shamim, Michael Laskowski
Tumor necrosis factor α (TNF-α) inhibitors have long been used as disease-modifying agents in immune disorders. Recently, research has shown a role of chronic neuroinflammation in the pathophysiology of neurodegenerative diseases such as Alzheimer disease, and interest has been generated in the use of anti-TNF agents and TNF-modulating agents for prevention and treatment. This article extensively reviewed literature on animal studies testing these agents. The results showed a role for direct and indirect TNF-α inhibition through agents such as thalidomide, 3,6-dithiothalidomide, etanercept, infliximab, exendin-4, sodium hydrosulfide, minocycline, imipramine, and atorvastatin...
2017: Journal of Central Nervous System Disease
https://www.readbyqxmd.com/read/28808198/ultrasonographic-evaluation-of-enthesitis-in-patients-with-ankylosing-spondylitis
#6
Huayong Zhang, Jun Liang, Junlan Qiu, Fan Wang, Lingyun Sun
The aim of this study was to assess sensitivity and responsiveness of power Doppler ultrasound (PDUS) in detecting enthesitis for ankylosing spondylitis (AS) patients compared to clinical examinations. Twenty AS patients initiating etanerceptunderwent clinical and PDUS examinations of six bilateral entheseal sites at baseline and after 1, 2 and 3 months of treatment. Clinical and PDUS examinations identified at least one entheseal lesion in nine (45%) and 19 (95%) patients, respectively. Furthermore, of 240 entheseal sites examined in these 20 patients, PDUS detected 123 entheseal lesions (51...
January 19, 2017: Journal of Biomedical Research
https://www.readbyqxmd.com/read/28807082/hearing-status-in-patients-with-rheumatoid-arthritis
#7
A Ahmadzadeh, M Daraei, M Jalessi, A A Peyvandi, E Amini, L A Ranjbar, A Daneshi
OBJECTIVE: Rheumatoid arthritis is thought to induce conductive hearing loss and/or sensorineural hearing loss. This study evaluated the function of the middle ear and cochlea, and the related factors. METHODS: Pure tone audiometry, speech reception thresholds, speech discrimination scores, tympanometry, acoustic reflexes, and distortion product otoacoustic emissions were assessed in rheumatoid arthritis patients and healthy volunteers. RESULTS: Pure tone audiometry results revealed a higher bone conduction threshold in the rheumatoid arthritis group, but there was no significant difference when evaluated according to the sensorineural hearing loss definition...
August 15, 2017: Journal of Laryngology and Otology
https://www.readbyqxmd.com/read/28804988/patterns-of-systemic-treatment-for-psoriatic-arthritis-in-the-united-states-2004-2015
#8
Moa P Lee, Joyce Lii, Yinzhu Jin, Rishi J Desai, Daniel H Solomon, Joseph F Merola, Seoyoung C Kim
OBJECTIVE: To examine trends in use of systemic disease-modifying antirheumatic drugs (DMARD) among patients with psoriatic arthritis (PsA) in the U.S. METHODS: Using claims data (2004-2015) from a large U.S. commercial healthplan, we identified patients with PsA who initiated DMARDs. We examined baseline patient characteristics and initial treatment patterns. We then assessed changes in the DMARD regimen over the 12-month period after the 1(st) DMARD initiation date...
August 13, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28794078/long-term-efficacy-and-safety-in-patients-with-rheumatoid-arthritis-continuing-on-sb4-or-switching-from-reference-etanercept-to-sb4
#9
Paul Emery, Jiří Vencovský, Anna Sylwestrzak, Piotr Leszczyński, Wieslawa Porawska, Barbara Stasiuk, Joanna Hilt, Zdenka Mosterova, Soo Yeon Cheong, Jeehoon Ghil
OBJECTIVES: SB4 (Benepali, Brenzys) is a biosimilar of reference etanercept (ETN). In a randomised, double-blind, 52-week study, SB4 demonstrated comparable efficacy and safety to ETN in patients with rheumatoid arthritis (RA). The open-label extension period evaluated long-term efficacy, safety and immunogenicity when continuing SB4 versus switching from ETN to SB4. METHODS: In the randomised, double-blind phase, patients received weekly subcutaneous administration of 50 mg SB4 or ETN with background methotrexate for up to 52 weeks...
August 9, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28792259/improvements-in-psoriasis-within-different-body-regions-vary-over-time-following-treatment-with-ixekizumab
#10
Andrew Blauvelt, Talia M Muram, Kyoungah See, Craig H Mallinckrodt, Jeffrey J Crowley, Peter van de Kerkhof
BACKGROUND: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A. OBJECTIVE: Examine the efficacy of ixekizumab in clearing psoriasis within different body regions. METHODS: Data from 3 placebo- (PBO) or PBO- and etanercept (ETN)-controlled trials were integrated. Patients with moderate-to-severe psoriasis were randomized to 12 weeks of PBO (UNCOVER-1, -2, -3, N = 792; UNCOVER-2, -3, N = 361), 50 mg ETN twice weekly (N = 740), or 80 mg ixekizumab every 2 (IXE Q2W; N = 1169; N = 736) or 4 weeks (IXE Q4W; N = 1165; N = 733) after a 160-mg starting dose...
August 9, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28791873/comparing-biologic-persistence-and-healthcare-costs-in-rheumatoid-arthritis-patients-initiating-subcutaneous-biologics
#11
Anagha Nadkarni, Donna McMorrow, Robert Fowler, David Smith
AIM: Comparing biologic persistence and healthcare costs between rheumatoid arthritis (RA) patients initiating first- or second-line subcutaneous abatacept, adalimumab, or etanercept. MATERIALS & METHODS: Retrospective, observational cohort study, which included adults with RA who initiated either of the three treatments between 29 July 2011 and 1 July 2015. Total healthcare costs were measured during baseline and follow-up. Biologic persistence was compared using multivariable Cox proportional hazards regression...
August 9, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28790869/etanercept-enbrel-%C3%A2-alternative-storage-at-ambient-temperature
#12
Edel Shannon, Joanne Daffy, Heather Jones, Andrea Paulson, Steven M Vicik
BACKGROUND: Biologic disease-modifying antirheumatic drugs, including tumor necrosis factor inhibitors such as etanercept (Enbrel(®)), have improved outcomes for patients with rheumatic and other inflammatory diseases, with sustained remission being the optimal goal for patients with rheumatoid arthritis. Flexible and convenient treatment options, compatible with modern lifestyle, are important in helping patients maintain treatment and manage their disease. Etanercept drug product (DP) is available in lyophilized powder (Lyo) for solution injection, prefilled syringe, and prefilled pen presentations and is typically stored under refrigerated conditions...
2017: Clinical Pharmacology: Advances and Applications
https://www.readbyqxmd.com/read/28779960/efficacy-and-safety-of-etanercept-in-the-treatment-of-sciatica-a-systematic-review-and-meta-analysis
#13
REVIEW
Shangfei Jing, Chenyuan Yang, Xiaofei Zhang, Shuzheng Wen, Yuankui Li
Etanercept might be promising to alleviate sciatica caused by lumbar disc herniation and spinal stenosis. However, the results remained controversial. We conducted a systematic review and meta-analysis to evaluate the efficacy of etanercept in patients with sciatica. PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched. Randomized controlled trials (RCTs) and Controlled clinical trials (CCT) assessing the efficacy of etanercept on sciatica caused by lumbar disc herniation and spinal stenosis were included...
August 2, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28776364/jaccoud-s-arthropathy-an-unusual-manifestation-of-idiopathic-retroperitoneal-fibrosis-rapid-improvement-of-symptoms-after-tocilizumab-treatment
#14
M Benucci, A Damiani, F Li Gobbi, V Grossi, M Infantino, A Arena, M Manfredi
Jaccoud's arthropathy (JA) is a chronic, non erosive, rheumatoid-like deformity associated with rheumatic fever (RF) and systemic lupus erythematosus and with other diseases such as psoriatic arthritis, connective tissue diseases, hypocomplementemic urticarial vasculitis, infections, sarcoidosis and neoplasia. We described a case of JA in a patient with cutaneous psoriasis but with a particular disease evolution associated with idiopathic retropritoneal fibrosis (IRF), evaluated with computed tomography, magnetic resonance and 18F-FDG PET/ CT...
August 3, 2017: Reumatismo
https://www.readbyqxmd.com/read/28771657/time-pasi-and-dlqi-of-psoriasis-patients-who-drop-out-of-clinical-trials-on-etanercept-due-to-lack-of-efficacy-a-pooled-analysis-from-ten-clinical-trials
#15
A Nast, M Dilleen, W Liyanage, L Aikman, P Szczypa, C Dressler
BACKGROUND: Patient-reported outcomes in psoriasis studies are assessed at specific study time points. If a treatment has not become effective by a certain time point, it may increase the likelihood of patients being dissatisfied and leaving a clinical study. OBJECTIVES: Generate evidence concerning the number of patients dropping out of etanercept trials over time including PASI and DLQI data. METHODS: Data from psoriasis patients in ten trials with etanercept were pooled...
August 3, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28770517/changes-in-healthcare-utilization-after-etanercept-initiation-in-patients-with-rheumatoid-arthritis-a-retrospective-claims-analysis
#16
Neil A Accortt, Jennifer Schenfeld, Eunice Chang, Elya Papoyan, Michael S Broder
INTRODUCTION: Effective treatment for rheumatoid arthritis (RA) may lead to lower overall and RA-related healthcare utilization. We evaluated healthcare utilization before and after initiation of the tumor necrosis factor inhibitor etanercept in patients with moderate to severe RA. METHODS: This retrospective cohort study used data from the MarketScan(®) claims database. Data from adult patients with RA newly exposed to etanercept between January 1, 2010 and December 31, 2013 were analyzed...
August 2, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28766398/assessing-joint-destruction-in-the-knees-of-patients-with-rheumatoid-arthritis-by-using-a-semi-automated-software-for-magnetic-resonance-imaging-therapeutic-effect-of-methotrexate-plus-etanercept-compared-with-methotrexate-monotherapy
#17
Hiroyuki Oka, Yuho Kadono, Satoru Ohashi, Tetsuro Yasui, Kumiko Ono, Ko Matsudaira, Jinju Nishino, Sakae Tanaka
OBJECTIVES: To evaluate the prevention of knee joint destruction and clinical efficacy of methotrexate (MTX) plus etanercept (ETN) compared with MTX monotherapy in patients with rheumatoid arthritis (RA) by using semi-automated software for magnetic resonance imaging (MRI) scan analysis. MATERIALS AND METHODS: This study enrolled patients with active moderate-to-severe RA who displayed an inadequate response to oral MTX at screening. Patients were assigned to receive either MTX plus ETN or MTX monotherapy (≥10 mg/week)...
August 2, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28758274/pregnancy-and-infant-outcomes-including-major-congenital-malformations-among-women-with-chronic-inflammatory-arthritis-or-psoriasis-with-and-without-etanercept-use
#18
Wendy J Carman, Neil A Accortt, Mary S Anthony, Janet Iles, Cheryl Enger
PURPOSE: Objectives were to quantify prevalence estimates of pregnancy and infant outcomes including major congenital malformations (MCMs) by etanercept (ETN) exposure among infants born to women with chronic inflammatory arthritis (cIA) or psoriasis (PsO). METHODS: Claims-based data delineated pregnancy exposures and outcomes of live or nonlive births among women with cIA and PsO (ETN exposed, unexposed) and general population (GP) comparators. Infant outcomes were determined for live-born infants covered by the mother's insurer...
July 31, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28757436/etanercept-and-corticosteroid-therapy-for-the-treatment-of-late-onset-idiopathic-pneumonia-syndrome
#19
Jonathan Thompson, Ziyan Yin, Anita D'Souza, Timothy Fenske, Mehdi Hamadani, Parameswaran Hari, J Douglas Rizzo, Marcelo Pasquini, Wael Saber, Nirav Shah, Bronwen E Shaw, Kaushik Shahir, Anjishnu Banerjee, William R Drobyski
Idiopathic pneumonia syndrome (IPS) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT) that typically occurs within the first 100 days after transplantation. Tumor necrosis alpha-α (TNF-α) has been shown to be a key mediator of IPS, and the TNF-α binding protein, etanercept, appears to improve IPS outcomes in small retrospective and prospective studies. IPS has also been observed to occur later (>100 days) after HSCT; however, little is known about the disease course and whether a TNF-α-based therapeutic strategy is efficacious in these patients...
July 27, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28756532/etanercept-is-effective-as-monotherapy-or-in-combination-with-methotrexate-in-rheumatoid-arthritis-subanalysis-of-an-observational-study
#20
Markus Gaubitz, Karl-Heinz Göttl, Olaf Behmer, Ralph Lippe, Thomas Meng, Peter-Andreas Löschmann
Approximately 30% of patients with rheumatoid arthritis receiving biological disease-modifying antirheumatic drugs (bDMARDs) take them as monotherapy. Although etanercept (ETN) monotherapy has been evaluated in clinical trials, data in the real-world setting are sparse. We compared the efficacy and safety of ETN, given alone or in combination with methotrexate (MTX), in routine clinical practice. This was a subanalysis of patients who received either ETN alone or ETN + MTX during a 52-week prospective, observational study conducted at 329 German centers...
July 30, 2017: Clinical Rheumatology
keyword
keyword
26126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"